secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silence Therapeutics plc (SLN)
CIK:        0001479615
Form:       8-K
Filed at:   2026-06-11T11:35:16+00:00
Accession:  0001193125-26-266705
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silence Therapeutics reports durable phlebotomy reduction and QoL gains from Phase 1 divesiran study at EHA 2026
--------------------------------------------------------------------------------

- 21 PV patients: 5 phlebotomies during active treatment vs 80 in prior 6 months; only 4 in 16-week follow-up.
- Median time to first phlebotomy was 287 days among 14 evaluable patients.
- Majority had improved MPN-10 symptom scores through Week 34, indicating better quality of life.
- Phase 2 SANRECO (Q6W and Q12W dosing) topline results expected August 2026.
- Divesiran well tolerated; mild injection-site reactions, no treatment-related SAEs or discontinuations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479615/000119312526266705/0001193125-26-266705-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479615/000119312526266705/sln-20260611.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-266705

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer